Peter Lawson
Stock Analyst at Barclays
(1.21)
# 3,602
Out of 4,898 analysts
106
Total ratings
34.94%
Success rate
-14.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $45.58 | -12.24% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.58 | +89.87% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.14 | +75.44% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.28 | +63.70% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $4.77 | +109.64% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $2.01 | +99.00% | 7 | May 12, 2025 | |
| XNCR Xencor | Maintains: Underweight | $22 → $6 | $8.85 | -32.20% | 2 | May 8, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $32 → $11 | $6.35 | +73.23% | 1 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $32 → $16 | $7.87 | +103.30% | 8 | May 2, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Overweight | $40 → $15 | $8.08 | +85.64% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $9.65 | +45.08% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.94 | +54.64% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.92 | +56.25% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.34 | +198.51% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $38.37 | +56.37% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $3.56 | +377.53% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $9.85 | +235.03% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $35.28 | +87.07% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $105 | $129.36 | -18.83% | 10 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $12.69 | +144.29% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $11.28 | +50.71% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $6.09 | +113.46% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.82 | +510.50% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $2.39 | +46.44% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $98.53 | +270.45% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $39.33 | +16.96% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $24.41 | +1,743.51% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.85 | +1,478.95% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $56.42 | -20.24% | 2 | Jan 23, 2018 |
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $45.58
Upside: -12.24%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.58
Upside: +89.87%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.14
Upside: +75.44%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.28
Upside: +63.70%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $4.77
Upside: +109.64%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.01
Upside: +99.00%
Xencor
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $8.85
Upside: -32.20%
Kura Oncology
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $6.35
Upside: +73.23%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $7.87
Upside: +103.30%
Bicycle Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $8.08
Upside: +85.64%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $9.65
Upside: +45.08%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.94
Upside: +54.64%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.92
Upside: +56.25%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.34
Upside: +198.51%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $38.37
Upside: +56.37%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $3.56
Upside: +377.53%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $9.85
Upside: +235.03%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $35.28
Upside: +87.07%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $129.36
Upside: -18.83%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $12.69
Upside: +144.29%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $11.28
Upside: +50.71%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $6.09
Upside: +113.46%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.82
Upside: +510.50%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.39
Upside: +46.44%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $98.53
Upside: +270.45%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $39.33
Upside: +16.96%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $24.41
Upside: +1,743.51%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.85
Upside: +1,478.95%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $56.42
Upside: -20.24%